Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316979 | 0.85 | HTR2C (0.43) | POLBMEN1KMT2A | |
| SCHEMBL4692053 | 0.69 | ALDH1A1 (0.39) | HPGDTSHRALDH1A1POLBS1PR1 | |
| SCHEMBL6311313 | 0.69 | BACE1 (0.35) | ALDH1A1POLBSIGMAR1KMT2A | |
| SCHEMBL5540890 | 0.63 | SIGMAR1 (0.46) | ALDH1A1S1PR1S1PR5FUCA1SIGMAR1 | |
| SCHEMBL25327452 | 0.63 | PDK1 (0.55) | TACR1DRD2BRD4 | |
| SCHEMBL1749081 | 0.62 | GSK3A (0.40) | HPGDTSHRALDH1A1FUCA1MEN1 | |
| SCHEMBL4657693 | 0.62 | RIPK1 (0.47) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4657697 | 0.62 | RIPK1 (0.47) | ALDH1A1POLBMEN1KMT2A | |
| Acetic Acid SCHEMBL28332665 | 0.61 | CYP2D6 (0.49) | TSHRALDH1A1POLBS1PR1S1PR5 | |
| SCHEMBL5041382 | 0.61 | SIGMAR1 (0.47) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | HPGD 2229/4885TSHR 975/4885ALDH1A1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.